EPEC mutant strains generated with the marker-less deletion strategy.
Abstract
Enteropathogenic E. coli (EPEC) is a diarrheagenic human pathogen. The hallmark of EPEC infection is the formation of the attaching and effacing (A/E) lesion in the intestinal epithelial cells, characterized by the effacement of brush border microvilli and the intimate bacterial attachment to the enterocyte in actin-rich pedestal-like structures. The locus of enterocyte effacement (LEE) in the EPEC genome encodes a type III protein secretion system (T3SS) that translocates multiple effector proteins into the host cell to subvert cellular functions for the benefit of the pathogen. These effectors are encoded both within and outside the LEE. In vitro cell culture infections have shown that LEE effectors are required for intimate bacterial attachment to the epithelial cells, whereas non-LEE effectors mostly play a role in modulating inflammation and cell apoptosis in the gut epithelium. We constructed a set of EPEC mutant strains harboring deletions in the complete repertoire of genes encoding T3SS effectors. Infection of human intestinal in vitro organ cultures (IVOC) with these mutant strains surprisingly revealed that non-LEE effectors are also needed to induce efficient A/E lesion formation in the intestinal mucosal tissue.
Keywords
- A/E lesion
- EPEC
- effectors
- infection
- IVOC
- T3SS
1. Introduction
1.1 Enteropathogenic E. coli
Enteropathogenic
1.2 Hallmark of EPEC gastrointestinal infection
The phenotype that defines EPEC infection is the attaching and effacing (A/E) lesion [2, 7]. By adhering to intestinal epithelial cells, EPEC subverts cytoskeletal processes of the host cell and produces the histopathological feature of the A/E lesion. This lesion, which was first described in 1980 [8], is characterized by the intimate attachment of the bacteria to the intestinal epithelial cells and elongation and effacement of the brush border microvilli. Later on it was shown that infection is also associated with cytoskeletal rearrangements, including the accumulation of polymerized F-actin in pedestal-like structures underneath the attached bacteria [9] (Figure 1). EPEC together with enterohemorrhagic

Figure 1.
Localized adherence (LA), intimate attachment, and EPEC A/E lesion formation in the intestinal epithelial surface. At an early stage, EPEC interacts in a non-intimate manner with the intestinal surface mainly through the BFP and EspA filament. After assembly of the translocation pore, EPEC injects translocated intimin receptor (Tir). Ser/Thr phosphorylation of Tir induces its anchoring in the enterocyte plasma membrane, leaving the TirM region exposed for the interaction with intimin. Subsequent Tir-intimin interaction triggers actin polymerization and pedestal formation underneath the attached bacterium. Tir phosphorylation of residue Y474 engages the host adaptor NcK, which later recruits N-WASP and WIP. N-WASP recruits the ARP2/3 complex, which induces actin nucleation and polymerization.
2. EPEC virulence factors
2.1 A pathogenicity island called LEE
The ability of EPEC to induce A/E lesions is related to a pathogenicity island (PAI) of 35 kb called the locus of enterocyte effacement (LEE) [14]. The LEE comprises 41 genes organized in 5 principal operons (LEE1-LEE5) and several smaller transcriptional units (Figure 2) [15, 16]. Orthologues of LEE are also found in other members of A/E pathogens [11]. The LEE encodes all the structural proteins necessary for the assembly of a filamentous type III secretion system (T3SS) injectisome on the bacterial cell envelope [17, 18]. The LEE also encodes transcriptional regulators (Ler, GrlR, and GrlA), translocator proteins (EspA, EspB, and EspD), six secreted effector proteins (including the translocated intimin receptor), the outer membrane protein intimin, molecular chaperones, and a lytic transglycosylase (EtgA) [19]. The mechanism of LEE regulation is complex and depends on environmental conditions, quorum sensing (QS), and several transcriptional regulators encoded within and outside the LEE [20, 21].
2.2 The type III secretion system
The type III secretion system is a macromolecular transport apparatus that is used by many gram-negative bacterial pathogens (e.g.,

Figure 2.
Effectors of EPEC E2348/69. (A) Representation of the LEE island and effector genes
2.3 Bundle-forming pilus (BFP)
Typical EPEC is endowed with a plasmid called pMAR2 which contains a 14-gene operon encoding the type IV pilus BFP [27, 28]. The BFP is a rope-like bundle, which allows EPEC to form microcolonies in a pattern called localized adherence and also mediates the initial interaction of bacteria with host cell surfaces (Figure 1) [29, 30, 31].
3. EPEC pathogenesis
EPEC tightly regulates its virulence genes in response to environmental conditions such as temperature [16], the increase of the pH of the small intestine [33, 34], and some hormones which are released during stress conditions [20]. Upon EPEC interaction with enterocytes, EspB and EspD proteins are inserted into the host cell membrane and assemble to form a translocation pore [25, 26]. EPEC then injects its own receptor called Tir, which is integrated into the plasma membrane in a hairpin loop topology, with the loop facing the outside of the cell where it serves as a receptor for the bacterial adhesin intimin [35, 36, 37]. Tir-intimin interaction induces clustering and dimerization of Tir, and this activates a signal cascade that starts with the phosphorylation of serine/threonine residues and leads to actin polymerization and pedestal formation underneath the attached bacterium [10, 38]. The most critical event for actin polymerization is the phosphorylation of the cytoplasmic Tir residue Y474 [39]. This induces a signal cascade which recruits the host cell adaptor Nck and N-WASP required to engage and activate the actin-nucleating ARP2/3 complex, which produces the actin nucleation and polymerization. Actin polymerization drives membrane protrusion and pedestal formation [10, 40] (Figure 1). Through the T3SS injectisome, EPEC translocates LEE-encoded effector proteins and additional effectors localized in mobile genetic element outside the LEE (Nle).
4. LEE effectors
Six effector proteins (EspG, EspZ, EspH, Map, Tir, and EspF) are encoded in the LEE island (Figure 2). Most of these, except EspZ, have important functions destabilizing the physiology of the intestinal epithelium, triggering cytoskeleton reorganization, inducing cytotoxicity and electrolyte imbalance which lead to diarrhea [11, 41]. The rapid onset of EPEC-induced diarrhea is likely induced by the cooperative action of Tir, Map, and EspF, which inhibits the sodium-D-glucose transporter (SGLT-1), the major water pump of the small intestine responsible for about 70% of the total fluid uptake [42]. In addition, Map and EspF reduce Na + absorption by the sodium-hydrogen exchanger (NHE3) [43], and EspG1/2 proteins alter the membrane targeting of the Cl-/OH-exchanger (DRA), resulting in reduced Cl-uptake. These processes result in the accumulation of salts in the gut lumen, which drives water loss from the mucosa [44].
Inhibition of endosomal trafficking by EspG1/2 reduces the level of cell surface receptors [45]. In addition, EspF and EspG induce mislocalization of aquaporins (AQP), thereby reducing epithelial water absorption [46]. Furthermore, EspB, Tir, EspF, and Map induce microvillus effacement, and this reduction of absorptive surface likely exacerbates EPEC diarrhea [47]. While EspF and Map synergistically disrupt TJs [48], EspG1/2 induces microtubule disruption contributing to TJ disruption [49]. The effector protein NleA also disrupts TJs by blocking the delivery of new TJ proteins [49, 50, 51]. The disruption of TJs increases intestinal permeability and thereby likely contributes to EPEC-induced diarrhea [52] (Figure 3).

Figure 3.
EPEC effector proteins altering epithelial cell function and inducing water loss and diarrhea. Tir, map, and EspF inhibit the sodium-D-glucose transporter. EspF reduces expression of the sodium-hydrogen exchanger NHE3. EspG and EspF induce mislocalization of aquaporins (AqP). EspG1/EspG2 alters membrane targeting of the Cl-/OH-exchanger. EspF, map, NleA, EspG1, and EspG2 disrupt tight junction complexes (TJ). EspB, Tir, EspF, and map induce microvilli effacement.
5. Non-LEE effectors
In EPEC prototype strain E2348/69, 17 functional Nle effectors are encoded in different integrative elements and prophages, frequently associated in gene clusters, with some effectors having duplicated gene copies and/or paralogs in different clusters [53] (Figure 2). EPEC infection is characterized by a weak inflammatory response [54]. Previous studies have shown that most Nle effectors and some LEE effectors inhibit the host immune response, which favors bacterial survival (Figure 4). Although NleF and NleH2 activate the NF-κB inflammatory pathway during early infection (ref), EPEC translocates several effectors that dampen the proinflammatory pathways of the cell [11]. Thus, a large number of Nle effectors inhibit host inflammation by different mechanisms, such as inhibition of the NF-κB (NleB, C, E, and H) and MAPK proinflammatory pathways (NleC and D) [55, 56, 57, 58], inhibition of the canonical (NleA) and noncanonical (NleF) inflammasomes [59], and inhibition of proliferation of lymphocytes and interleukin production (LifA) [60, 61].

Figure 4.
Schematic representation of multifunctional and overlapping effectors to control host immune response. The NF-κB proinflammatory pathway is activated by NleF and NleH2 and is inhibited by NleE, NleB, NleH1, Tir, and NleC. NleC and NleD inhibit the MAPK proinflammatory pathway. EspF, EspJ, EspH, and EspB prevent macrophage phagocytosis. NleA disrupts inflammasome activation, and LifA inhibits IL-2 and IL-4 production and lymphocyte proliferation. While EspF and map induce intrinsic apoptosis, EspZ counteracts these effects by stabilizing mitochondrial membrane potential. NleH1/NleH2 and NleF inhibit intrinsic apoptosis, and NleF, NleD, and NleB counteract extrinsic apoptosis.
The control of the epithelial cell death response to microbial infection is pivotal for pathogens and the host. Pathogens that are colonizing the epithelium need to prevent cell death to preserve their replicative foothold; by contrast, the host needs to eliminate infected cells in order to minimize tissue damage [62]. During infection of the intestinal epithelial cells, surface properties of EPEC are recognized by cell surface death receptors and induce extrinsic apoptotic pathways, while T3SS effectors (Map and EspF) trigger cytochrome c release, activation of caspases, and downstream intrinsic apoptotic pathways [11, 24]. Interestingly, early stages of apoptosis can be observed during EPEC infection, but late stages are not evident because EPEC translocates effector proteins that antagonize these pro-apoptotic effects. NleD and NleB interfere with the pro-apoptotic death receptor signaling and disrupt the downstream extrinsic apoptosis [63, 64]. NLeH1/2 and EspZ also inhibit intrinsic apoptosis and promote host cell survival [65, 66, 67] (Figure 4). NleF directly inhibits caspases involved in both intrinsic and extrinsic apoptosis pathways, including caspases 4, 8, and 9 [68]. In addition, EspZ localizes to the cytoplasmic side of the plasma membrane at the site of bacterial attachment and interacts with the translocator protein EspD. It has been proposed that EspZ indirectly prevents cell death by downregulating protein translocation and protecting cells from an overdose of effector proteins. Consistently, a Δ
6. Classical methodologies to study effector functions
Most research on EPEC effectors has been conducted by generating deletion mutants in a single or a few effector genes that are later complemented with multicopy plasmids overexpressing the effector(s). In addition, ectopic expression of individual effectors by plasmid transfection of the host cell has been applied. Both situations are prone to effector overexpression resulting in nonphysiological levels of effectors inside the host cell, which could alter effector activities. In addition, effectors often have synergistic and overlapping functions that cannot be fully appreciated by single mutations and individual transfection experiments [11, 54]. In order to overcome these limitations, we employed a marker-less gene deletion strategy to delete the whole repertoire of known effector genes found in the genome of the prototypical EPEC strain E2348/69 [32]. The genome engineering method for sequential deletion of EPEC effectors was based on the marker-less gene deletion technique described by Posfai et al. [71] and is illustrated in Figure 5.

Figure 5.
Marker-less gene deletion strategy of EPEC effector genes. Deletions using pGE-suicide plasmids with I-SceI sites and mutant alleles assembled by fusing homology regions (HRs) flanking the targeted effector gene(s). Co-integrants are identified by the Kanamycin resistance phenotype. Expression of the I-SceI in vivo from helper plasmid induces double-strand brakes that are repaired by homologous recombination. Depending on the HRs involved in this second recombination, either the WT or the mutant allele can be obtained. Figure from [
Using this strategy, a set of EPEC mutants with sequential deletions of effectors was generated (Table 1), ultimately resulting in strains expressing only Tir and EspZ (EPEC2), Tir (EPEC1), and the effector-less strain EPEC0 (Table 1). This approach proved to be effective to specifically modify the genome of EPEC E2348/69, avoiding the introduction of unintended alterations in the genome and leaving no sequence “scars” or antibiotic resistance genes in the chromosome as demonstrated by whole-genome sequencing [32]. Besides, the deletion mutant strains showed normal growth and maintained functional T3SS injectisomes. In addition, they allowed the translocation of individual effectors from single-copy chromosomal genes under endogenous regulation, showing the expected phenotypes without the background of the other effectors [32]. Hence these mutant strains are an excellent tool to investigate the role of individual effectors and specific combinations maintaining physiological protein levels in the context of infection.
Strain | Effector genes remaining* |
---|---|
WT | All |
EPEC2 | |
EPEC1 | |
EPEC0 | None |
EPEC9 | |
EPEC2-LEE+ |
Table 1.
Encoded effectors in the indicated IEs and PPs.
7. LEE effectors are sufficient for intimate adhesion of EPEC to the epithelial cells in vitro
When EPEC bacteria adhere in vitro to cultured cells, there is an accumulation of actin filaments in the cytoplasm beneath the adherent bacteria, due to a signal cascade triggered by intimin-Tir interaction [35, 38]. Using the effector deletion mutants of EPEC, we demonstrated that the LEE effector Tir along with intimin is necessary and sufficient to induce these cytoskeletal rearrangements during in vitro infection of HeLa cells. Strains EPEC2 (bearing EspZ and Tir) and EPEC1 (bearing only Tir) were able to induce actin-pedestal formation underneath attached bacteria similar to the EPEC wild type (WT) (Figure 6). As expected because of the essential role of Tir in this process, infection of HeLa cells with the effector-less mutant EPEC0 did not induce any actin-pedestal formation (Figure 6). These data demonstrate that the individual translocation of Tir by EPEC1 is sufficient to trigger actin pedestals in HeLa cells and that non-LEE effectors are dispensable for this phenotype during in vitro infection of cultured cells.

Figure 6.
Infection of HeLa cells with EPEC WT and effector mutant strains. Immunofluorescence confocal microscopy of HeLa cells infected with EPEC WT, EPEC2, EPEC1, and EPEC0 for 1.5 h using a MOI of 200. EPEC is labeled with anti-intimin-280 serum (green), actin is stained with TRITC phalloidin (red), and cell nuclei are labeled with DAPI (gray). Actin polymerization beneath adherent bacteria is observed in EPEC WT, EPEC2, and EPEC1. Scale bar 5 μm. Figure from [
8. Non-LEE effectors are required for efficient A/E lesion formation in intestinal tissue
EPEC pathogenic mechanisms have been widely investigated by in vitro infection of cultured epithelial cell lines, albeit in most cases these cells are non-polarized and are not from intestinal origin. In addition, EPEC infection studies in vivo are hindered because EPEC is a human-restricted pathogen [72]. A surrogate model established to investigate A/E pathogenesis in vivo is the mouse pathogen
Strain | Effector genes remaining* | Biopsies with A/E lesions positive/total (%) |
---|---|---|
WT | All | 13/17 (76) |
EPEC2 | 0/6 (0) | |
EPEC1 | 0/6 (0) | |
EPEC0 | None | 0/5 (0) |
EPEC9 | 5/6 (83) | |
EPEC2-LEE+ | 0/5 (0) |
Table 2.
Human duodenal biopsies infected by EPEC WT and EPEC effector mutants.
Encoded effectors in the indicated IEs and PPs.

Figure 7.
Scanning electron microscopy of human duodenal biopsies infected with EPEC WT and mutant strains EPEC2, EPEC1, EPEC0, EPEC9, and EPEC2-LEE+. EPEC WT and EPEC9 induce characteristic A/E lesions with bacterial microcolony formation (asterisk) and microvilli elongation around bacterial colonies (arrowheads). In contrast, biopsies infected with EPEC2, EPEC1, EPEC0, and EPEC2-LEE+ lack adherent bacteria and A/E lesions and show a normal microvillous brush border. Scale bar 2 μm. Figure from [
9. Conclusions and future perspectives
The marker-less gene deletion strategy enabled the generation of effector-less strains of EPEC O127:H6 using the prototypical strain E2348/69 [32]. Given the conservation of the recombination machinery among
In addition to their potential for basic studies, the EPEC effector mutant strains may have different applications. For instance, EPEC (and other pathogenic) strains lacking multiple effectors are likely to be strongly attenuated, but they maintain the external antigenicity of the wild-type strain. Thus, an EPEC mutant strain with a functional T3SS and the minimum set of effectors necessary to colonize the intestinal surface could be a good vaccine candidate. Further, EPEC mutant strains with the ability to attach to the human intestine could also be engineered to translocate heterologous protein antigens to generate protection against other enteric pathogens causing diarrhea, including EHEC strains [77, 78, 79, 80]. Lastly, the EPEC effector mutant strains may also have the potential to deliver therapeutic proteins to the intestinal epithelium, for instance, to combat inflammation and autoimmune disorders in the gastrointestinal tract [81].
Acknowledgments
We acknowledge support for the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
References
- 1.
Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli . Nature Reviews Microbiology. 2004;2 :123-139 - 2.
Chen HD, Frankel G. Enteropathogenic Escherichia coli : Unravelling pathogenesis. FEMS Microbiology Reviews. 2005;29 (1):83-98 - 3.
Tlaskalova-Hogenova H et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunology Letters. 2004; 93 (2-3):97-108 - 4.
Hicks S et al. Role of intimin and bundle-forming pili in enteropathogenic Escherichia coli adhesion to pediatric intestinal tissue in vitro. Infection and Immunity. 1998;66 (4):1570-1578 - 5.
Nataro JP, Kaper JB. Diarrheagenic Escherichia coli . Clinical Microbiology Reviews. 1998;11 (1):142-201 - 6.
Ochoa TJ et al. New insights into the epidemiology of enteropathogenic Escherichia coli infection. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102 (9):852-856 - 7.
Garmendia J, Frankel G, Crepin VF. Enteropathogenic and enterohemorrhagic Escherichia coli infections: Translocation, translocation, translocation. Infection and Immunity. 2005;73 (5):2573-2585 - 8.
Ulshen MH, Rollo JL. Pathogenesis of Escherichia coli gastroenteritis in man--another mechanism. The New England Journal of Medicine. 1980;302 (2):99-101 - 9.
Knutton S et al. Actin accumulation at sites of bacterial adhesion to tissue culture cells: Basis of a new diagnostic test for enteropathogenic and enterohemorrhagic Escherichia coli . Infection and Immunity. 1989;57 (4):1290-1298 - 10.
Lai Y et al. Intimate host attachment: Enteropathogenic and enterohaemorrhagic Escherichia coli . Cellular Microbiology. 2013;15 (11):1796-1808 - 11.
Wong AR et al. Enteropathogenic and enterohaemorrhagic Escherichia coli : Even more subversive elements. Molecular Microbiology. 2011;80 (6):1420-1438 - 12.
Collins JW et al. Citrobacter rodentium: Infection, inflammation and the microbiota. Nature Reviews. Microbiology. 2014; 12 (9):612-623 - 13.
Mundy R et al. Citrobacter rodentium of mice and man. Cellular Microbiology. 2005; 7 (12):1697-1706 - 14.
McDaniel TK et al. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92 (5):1664-1668 - 15.
Elliott SJ et al. The locus of enterocyte effacement (LEE)-encoded regulator controls expression of both LEE- and non-LEE-encoded virulence factors in enteropathogenic and enterohemorrhagic Escherichia coli . Infection and Immunity. 2000;68 (11):6115-6126 - 16.
Yerushalmi G et al. Dynamics of expression and maturation of the type III secretion system of enteropathogenic Escherichia coli . Journal of Bacteriology. 2014;196 (15):2798-2806 - 17.
Daniell SJ et al. The filamentous type III secretion translocon of enteropathogenic Escherichia coli . Cellular Microbiology. 2001;3 (12):865-871 - 18.
Gaytán MO et al. Type three secretion system in attaching and effacing pathogens. Frontiers in Cellular and Infection Microbiology. 2016; 6 :129 - 19.
García-Gómez E et al. The muramidase EtgA from enteropathogenic Escherichia coli is required for efficient type III secretion. Microbiology. 2011;157 (Pt 4):1145-1160 - 20.
Franzin FM, Sircili MP. Locus of enterocyte effacement: A pathogenicity island involved in the virulence of enteropathogenic and enterohemorrhagic subjected to a complex network of gene regulation. BioMed Research International. 2015; 2015 :534738 - 21.
Furniss RCD, Clements A. Regulation of the locus of enterocyte effacement in attaching and effacing pathogens. Journal of Bacteriology. 2018; 200 (2):e00336-17 - 22.
Portaliou AG et al. Type III secretion: Building and operating a remarkable nanomachine. Trends in Biochemical Sciences. 2016; 41 (2):175-189 - 23.
Raymond B et al. Subversion of trafficking, apoptosis, and innate immunity by type III secretion system effectors. Trends in Microbiology. 2013; 21 (8):430-441 - 24.
Santos AS, Finlay BB. Bringing down the host: Enteropathogenic and enterohaemorrhagic Escherichia coli effector-mediated subversion of host innate immune pathways. Cellular Microbiology. 2015;17 (3):318-332 - 25.
Ide T et al. Characterization of translocation pores inserted into plasma membranes by type III-secreted Esp proteins of enteropathogenic Escherichia coli . Cellular Microbiology. 2001;3 (10):669-679 - 26.
Luo W, Donnenberg MS. Interactions and predicted host membrane topology of the enteropathogenic Escherichia coli translocator protein EspB. Journal of Bacteriology. 2011;193 (12):2972-2980 - 27.
Stone KD et al. A cluster of fourteen genes from enteropathogenic Escherichia coli is sufficient for the biogenesis of a type IV pilus. Molecular Microbiology. 1996;20 (2):325-337 - 28.
Brinkley C et al. Nucleotide sequence analysis of the enteropathogenic Escherichia coli adherence factor plasmid pMAR7. Infection and Immunity. 2006;74 (9):5408-5413 - 29.
Ramboarina S et al. Structure of the bundle-forming pilus from enteropathogenic Escherichia coli . The Journal of Biological Chemistry. 2005;280 (48):40252-40260 - 30.
Hyland RM et al. The bundlin pilin protein of enteropathogenic Escherichia coli is an N-acetyllactosamine-specific lectin. Cellular Microbiology. 2008;10 (1):177-187 - 31.
Saldana Z et al. The Escherichia coli common Pilus and the bundle-forming Pilus act in concert during the formation of localized adherence by EnteropathogenicE. coli . Journal of Bacteriology. 2009;191 (11):3451-3461 - 32.
Cepeda-Molero M et al. Attaching and effacing (A/E) lesion formation by enteropathogenic E. coli on human intestinal mucosa is dependent on non-LEE effectors. PLoS Pathogens. 2017;13 (10):e1006706 - 33.
Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Danish Medical Bulletin. 1999; 46 (3):183-196 - 34.
Shin S et al. An activator of glutamate decarboxylase genes regulates the expression of enteropathogenic Escherichia coli virulence genes through control of the plasmid-encoded regulator, Per. Molecular Microbiology. 2001;41 (5):1133-1150 - 35.
Kenny B et al. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell. 1997;91 (4):511-520 - 36.
Frankel G et al. Generation of Escherichia coli intimin derivatives with differing biological activities using site-directed mutagenesis of the intimin C-terminus domain. Molecular Microbiology. 1998;29 (2):559-570 - 37.
Luo Y et al. Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex. Nature. 2000;405 (6790):1073-1077 - 38.
Frankel G, Phillips AD. Attaching effacing Escherichia coli and paradigms of Tir-triggered actin polymerization: Getting off the pedestal. Cellular Microbiology. 2008;10 (3):549-556 - 39.
Devinney R et al. Tir tyrosine phosphorylation and pedestal formation are delayed in enteropathogenic Escherichia coli sepZ::TnphoA mutant 30-5-1(3). Infection and Immunity. 2001;69 (1):559-563 - 40.
Goosney DL, de Grado M, Finlay BB. Putting E. coli on a pedestal: A unique system to study signal transduction and the actin cytoskeleton. Trends in Cell Biology. 1999;9 (1):11-14 - 41.
Guttman JA, Finlay BB. Subcellular alterations that lead to diarrhea during bacterial pathogenesis. Trends in Microbiology. 2008; 16 (11):535-542 - 42.
Dean P et al. Potent diarrheagenic mechanism mediated by the cooperative action of three enteropathogenic Escherichia coli -injected effector proteins. Proceedings of the National Academy of Sciences of the United States of America. 2006;103 (6):1876-1881 - 43.
Simpson N et al. The enteropathogenic Escherichia coli type III secretion system effector map binds EBP50/NHERF1: Implication for cell signalling and diarrhoea. Molecular Microbiology. 2006;60 (2):349-363 - 44.
Gill RK et al. Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli . The Journal of Clinical Investigation. 2007;117 (2):428-437 - 45.
Clements A et al. Enterohaemorrhagic Escherichia coli inhibits recycling endosome function and trafficking of surface receptors. Cellular Microbiology. 2014;16 (11):1693-1705 - 46.
Guttman JA et al. Aquaporins contribute to diarrhoea caused by attaching and effacing bacterial pathogens. Cellular Microbiology. 2007; 9 (1):131-141 - 47.
Iizumi Y et al. The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function. Cell Host & Microbe. 2007;2 (6):383-392 - 48.
Dean P, Kenny B. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Molecular Microbiology. 2004;54 (3):665-675 - 49.
Glotfelty LG et al. Enteropathogenic E. coli effectors EspG1/G2 disrupt microtubules, contribute to tight junction perturbation and inhibit restoration. Cellular Microbiology. 2014;16 (12):1767-1783 - 50.
Thanabalasuriar A et al. The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli . Cellular Microbiology. 2010;12 (1):31-41 - 51.
Kim J et al. The bacterial virulence factor NleA inhibits cellular protein secretion by disrupting mammalian COPII function. Cell Host & Microbe. 2007; 2 (3):160-171 - 52.
Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nature Reviews. Microbiology. 2010;8 (1):26-38 - 53.
Iguchi A et al. Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. Journal of Bacteriology. 2009;191 (1):347-354 - 54.
Dean P, Kenny B. The effector repertoire of enteropathogenic E. coli : Ganging up on the host cell. Current Opinion in Microbiology. 2009;12 (1):101-109 - 55.
Baruch K et al. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. The EMBO Journal. 2011; 30 (1):221-231 - 56.
Nadler C et al. The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathogens. 2010; 6 (1):e1000743 - 57.
Sham HP et al. Attaching and effacing bacterial effector NleC suppresses epithelial inflammatory responses by inhibiting NF-{kappa}B and p38 mitogen-activated protein kinase activation. Infection and Immunity. 2011; 79 (9):3552-3562 - 58.
Gao X et al. NleB, a bacterial effector with glycosyltransferase activity, targets GADPH function to inhibit NF-κB activation. Cell Host & Microbe. 2013; 13 (1):87-99 - 59.
Yen H, Sugimoto N, Tobe T. Enteropathogenic Escherichia coli uses NleA to inhibit NLRP3 inflammasome activation. PLoS Pathogens. 2015;11 (9):e1005121 - 60.
Abu-Median AB et al. Functional analysis of lymphostatin homologues in enterohaemorrhagic Escherichia coli . FEMS Microbiology Letters. 2006;258 (1):43-49 - 61.
Klapproth JM et al. A large toxin from pathogenic Escherichia coli strains that inhibits lymphocyte activation. Infection and Immunity. 2000;68 (4):2148-2155 - 62.
Kim M et al. Bacterial interactions with the host epithelium. Cell Host & Microbe. 2010; 8 (1):20-35 - 63.
Pearson JS et al. A type III effector antagonizes death receptor signalling during bacterial gut infection. Nature. 2013; 501 (7466):247-251 - 64.
Wong Fok Lung T et al. The cell death response to enteropathogenic Escherichia coli infection. Cellular Microbiology. 2014;16 (12):1736-1745 - 65.
Roxas JL et al. The enteropathogenic Escherichia coli -secreted protein EspZ inhibits host cell apoptosis. Infection and Immunity. 2012;80 (11):3850-3857 - 66.
Hemrajani C et al. NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection. Proceedings of the National Academy of Sciences. 2010;107 (7):3129-3134 - 67.
Royan SV et al. Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-kappaB activation. Molecular Microbiology. 2010;78 (5):1232-1245 - 68.
Blasche S et al. The E. coli effector protein NleF is a Caspase inhibitor. PLoS One. 2013;8 (3):e58937 - 69.
Berger CN et al. EspZ of enteropathogenic and enterohemorrhagic Escherichia coli regulates type III secretion system protein translocation. MBio. 2012;3 (5):e00317-12 - 70.
Mills E et al. Real-time analysis of effector translocation by the type III secretion system of enteropathogenic Escherichia coli . Cell Host & Microbe. 2008;3 (2):104-113 - 71.
Posfai G et al. Markerless gene replacement in Escherichia coli stimulated by a double-strand break in the chromosome. Nucleic Acids Research. 1999;27 (22):4409-4415 - 72.
Hill SM, Phillips AD, Walker-Smith JA. Enteropathogenic Escherichia coli and life threatening chronic diarrhoea. Gut. 1991;32 (2):154-158 - 73.
Deng W et al. Citrobacter rodentium translocated intimin receptor (Tir) is an essential virulence factor needed for actin condensation, intestinal colonization and colonic hyperplasia in mice. Molecular Microbiology. 2003; 48 (1):95-115 - 74.
Knutton S, Lloyd DR, McNeish AS. Adhesion of enteropathogenic Escherichia coli to human intestinal enterocytes and cultured human intestinal mucosa. Infection and Immunity. 1987;55 (1):69-77 - 75.
Schüller S et al. Tir phosphorylation and Nck/N-WASP recruitment by enteropathogenic and enterohaemorrhagic Escherichia coli during ex vivo colonization of human intestinal mucosa is different to cell culture models. Cellular Microbiology. 2007;9 (5):1352-1364 - 76.
McDaniel TK, Kaper JB. A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype onE. coli K-12. Molecular Microbiology. 1997;23 (2):399-407 - 77.
Riquelme-Neira R et al. Vaccination with DNA encoding truncated enterohemorrhagic Escherichia coli (EHEC) factor for adherence-1 gene (efa-1′) confers protective immunity to mice infected withE. coli O157:H7. Frontiers in Cellular and Infection Microbiology. 2016;5 :104-104 - 78.
Szu SC, Ahmed A. Clinical studies of Escherichia coli O157:H7 conjugate vaccines in adults and young children. Microbiology Spectrum. 2014;2 (6):1-7 - 79.
Rabinovitz BC et al. The intranasal vaccination of pregnant dams with Intimin and EspB confers protection in neonatal mice from Escherichia coli (EHEC) O157:H7 infection. Vaccine. 2016;34 (25):2793-2797 - 80.
Marcato P et al. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infection and Immunity. 2005; 73 (10):6523-6529 - 81.
Piñero-Lambea C, Ruano-Gallego D, Fernández LÁ. Engineered bacteria as therapeutic agents. Current Opinion in Biotechnology. 2015; 35 :94-102